Key takeaways
- We found no published controlled study of TB-500 in people (21 November 2026), and FDA staff found no clinical studies or human exposure data for it by any route.
- FDA staff identified no toxicity studies of TB-500 in animals or the laboratory, and wrote that, by the routes proposed to them, it “may pose a significant risk for immunogenicity”, the tendency to provoke an immune response.
- In a draft policy, HHS calls FDA staff’s safety concerns “inferential rather than observed”; neither agency cites a controlled human study of TB-500.
- The registered trial we found measures adverse events in a planned 80 patients aged 40 to 75, leaves out several groups, including pregnant and breastfeeding people, and has no results.
- In November 2026, Australia’s TGA found no detectable TB-500 in three products from one brand whose labels listed it.
01TB-500 side effects at a glance: who has recorded what
Who has recorded what about TB-500 safety, dated 21 November 2026. FDA’s adverse-event data are in the section on reports below.
A trial with no results yet
We found one randomised, placebo-controlled trial of TB-500 registered, and it is recruiting. Its primary measures are adverse events, and no results are posted.
Regulators’ reviews
FDA staff found no human exposure data, call the risks in people unknown and flag “a significant risk for immunogenicity”; a draft HHS policy calls their concerns inferential; the TGA tested products.
One uncontrolled report
Three patients received TB-500 with several other agents. The report recorded no adverse events; its authors write that these approaches “remain investigational, with unresolved questions concerning safety”.
| Source | What it covers | What it recorded |
|---|---|---|
| Controlled studies in people | PubMed and ClinicalTrials.gov, searched 21 Nov 2026 | None published. One registered phase 1/2 trial, NCT07487363, is recruiting, with no results |
| FDA staff, 2026 review | Published studies and FDA’s own records, in people, animals and cells | No clinical studies or human exposure data by any route; no toxicity studies in animals or the laboratory; potential safety risks in humans “are unknown”; by the routes proposed to them, it “may pose a significant risk for immunogenicity” |
| FDA compounding page, 2026 | TB-500, listed as “Thymosin beta-4, fragment (LKKTETQ)” | “May pose risk for immunogenicity for certain routes of administration”; FDA “has not identified any human exposure data” |
| HHS policy appendix, 2026 | TB-500 in a draft compounding policy | Calls FDA staff’s safety concerns “inferential rather than observed”; cites no controlled study of TB-500 in people |
| Case report, 2026 | Three patients given TB-500 with several other agents; no control group | “None reported” under adverse events; the authors: “remain investigational, with unresolved questions concerning safety” |
| TGA laboratory, Nov 2026 | Three products from one brand whose labels listed TB-500 | “No TB-500 detected” in each |
Small, short or uncontrolled records can show that common, immediate problems were not obvious. They cannot show that uncommon or delayed ones do not happen. Why that gap matters for every research peptide: the general safety question.
02Has TB-500 been tested for safety in people?
Not in a completed study. We found one registered trial under way and one published uncontrolled report (PubMed and ClinicalTrials.gov, 21 November 2026).
The trial. NCT07487363, sponsored by Hudson Biotech, is a randomised, placebo-controlled phase 1/2 study planned for 80 adults aged 40 to 75 with stable atherosclerotic cardiovascular disease, in three sequential groups, with a quarter of each group on placebo. Its primary measures are how many participants have any adverse event that starts during treatment, over 12 weeks, and how many have a serious one, over 28 days. It began on 5 February 2026 and is recruiting; primary completion is estimated for February 2027, and no results are posted (record last updated 12 November 2026).
Who the trial leaves out, among others (the registry lists the exact limits):
- Anyone under 40 or over 75, and healthy volunteers.
- People who are pregnant or breastfeeding.
- People with active cancer needing systemic treatment in the past two years, other than treated non-melanoma skin cancer.
- People with autoimmune disease needing systemic immunosuppression, or on long-term corticosteroids above replacement levels.
- People with severe kidney impairment, significant liver impairment or advanced heart failure.
- People with a known hypersensitivity to peptide therapeutics.
When results come, they will describe the people enrolled, not these groups.
The published report. A 2026 case report describes three patients given TB-500 and BPC-157 together with other agents, without a control group. Its table records “None reported” under adverse events. Its authors write that these peptide approaches “remain investigational, with unresolved questions concerning safety”. With several agents and no control group, it cannot show anything about TB-500 itself.
The full protein is a separate record. Registered phase 1 studies of the full 43-amino-acid protein, thymosin β4, were in healthy volunteers and did not give TB-500; FDA staff write that the two “are not the same substance”. The difference: TB-500 vs thymosin beta-4.
03What have regulators said about TB-500 safety?
FDA staff, 2026. Reviewing TB-500 for compounding, FDA staff found no clinical studies or human exposure data for it by any route and concluded that “potential safety risks associated with the use of TB-500 in humans are unknown”. They identified no toxicity studies of TB-500 in animals or the laboratory: none of single or repeated exposure, genetic damage, reproduction or cancer. They wrote that, by the routes proposed to them, TB-500 “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities”, and found no clinical study assessing either. Immunogenicity is the tendency to provoke an immune response; FDA staff write that the consequences of one “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions”.
FDA’s compounding page (content current 22 April 2026) lists TB-500 as “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”. It says compounded products containing it “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities”, that FDA “has not identified any human exposure data”, and that FDA lacks information on “whether it would cause harm if administered to humans”.
HHS, 2026. HHS’s appendix to its October 2026 compounding policy, which the Federal Register notice calls a draft that “is not binding on HHS or the public”, calls the safety concerns FDA staff identified “inferential rather than observed”, says the parent protein has “a controlled human safety record across several routes”, and says the fragment is “rapidly truncated in human serum”. FDA staff write that the parent protein and TB-500 “are not the same substance”, and HHS cites no controlled study of TB-500 in people. Background: the HHS peptide policy.
Australia. The TGA’s advisory of 5 November 2026 says that peptide products, alone or with other medicines, “can cause serious side effects”, and its Chief Medical Adviser warned of “a serious risk of a major allergic response, including anaphylaxis” from unapproved peptide products.
04What adverse-event reports name TB-500 or thymosin beta-4?
FDA’s search. FDA staff searched FDA’s adverse-event database for TB-500 reports through 26 March 2025 and retrieved none. FDA’s complaint system for foods, supplements and cosmetics held two cases about “blended TB-500 and BPC-157”, without safety assessments. FDA’s separate review of BPC-157 describes a woman who used a product labelled for “research purposes only” that contained BPC-157 and TB-500 and developed widespread darkening of the skin and darkening of the gums, which returned when she used it again and did not recur after she stopped. FDA staff judged the reactions “likely due to the drug product”, but “because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs.” In FDA’s public data, that report lists BPC-157 as its only product, coded “suspected product contamination”, “gingival hyperpigmentation”, “flushing”, “ephelides”, “skin discolouration”, “hot flush”, “erythema” and “lip discolouration”, so a search for TB-500 does not find it.
Our search. On 21 November 2026 we searched FDA’s public adverse-event data (FAERS, through openFDA, updated to 28 October 2026) for the product or ingredient names TB-500, TB500, “TB 500”, LKKTETQ, timbetasin and thymosin beta-4 in its spellings, and for products named only “thymosin”. The counts are ours.
TB-500 by name. One report names TB-500. It is a 2026 consumer report that lists a product labelled as a blend of GHK-Cu, BPC-157 and TB-500 among other products the person used, not as a suspect. The reporter named chorionic gonadotrophin and Ozempic (semaglutide), both prescription medicines, as the suspects, and the report is coded “adverse drug reaction”, “malignant lymphoid neoplasm” and “product dispensed by unauthorised provider”, and coded as serious. It does not record how the blend was used.
Thymosin beta-4 by name. Four reports name thymosin beta-4, and none records whether the product was TB-500 or the full protein. Three name it as a suspect: a 2024 consumer report that also names Kesimpta (ofatumumab), a prescription medicine, coded “drug ineffective” and not serious; and two 2026 reports that also name BPC-157 and other suspect products, one coded “malaise”, “blood insulin decreased”, “product dispensing error”, “product label issue”, “wrong product administered” and “manufacturing production issue”, the other “histamine abnormal” and “product quality issue”, both coded as serious. The fourth, a 2023 consumer report, lists thymosin beta-4 among more than 20 other products the person used; the reporter named three medicines approved or licensed in the US as the suspects, and the report is coded “impaired gastric emptying”, “mast cell activation syndrome”, “small fibre neuropathy”, “obesity”, “hepatic enzyme increased”, “blood potassium increased” and “hypertension”.
“Thymosin” alone. Another 47 reports name only “thymosin”, which does not say which thymosin peptide was meant; 30 of them come from China. One, a 2021 US consumer report, names “thymosin” as a suspect together with a BPC-157 product; it is coded as serious, and among its coded terms is “product sterility lacking”. Its other two coded terms name a route of administration, which our pages do not print (why).
How to read these reports. FDA staff write that “there is no certainty that a reported AE was due to the suspect product”, and that FDA “does not receive all AE reports that may potentially occur with a product, especially for compounded products”. openFDA tells users to “assume all results are unvalidated”. None of these reports gives a rate or shows a cause.
Had a reaction to any product? Seek medical care first, then report it: how to report a reaction in the US, UK or Australia.
05Does a TB-500 vial hold what its label says?
A regulator’s laboratory finding. In an advisory of 5 November 2026, the TGA published laboratory results for products from one brand, identified when it assisted a New South Wales police investigation. For three products labelled as containing TB-500, one with BPC-157 and two with several other ingredients, the finding was “No TB-500 detected”. The TGA concluded that consumers cannot rely on these labels to know what substance, or what amount, a product contains. That advisory covers that brand only.
Earlier findings. A French horse-racing laboratory that analysed products sold as TB500 and TB1000 reported in 2023 that their content was “not systematically consistent” with earlier descriptions of them. Even paperwork can disagree with the molecule: FDA staff noted that the molecular formula and one CAS registry number in the nomination they received for TB-500 matched “neither TB-500 free base nor TB-500 acetate”.
Three lines that show what a TB-500 lab report actually covers:
The report should give a mass result and say which molecule it matches. As FDA describes it, TB-500 is 889.01 g/mol; PubChem lists the full thymosin β4 protein at about 4,963 g/mol.
Purity says how much of the sample is the main peptide. It does not say which peptide that is, so it cannot replace the identity line.
The batch number must match the vial, and the lab and the test date must be named. A report for another batch says nothing about yours.
Each line explained, and what it means when one is missing: how to read a COA. Other documented cases: contamination and mislabeling.
06What we don’t know about TB-500 side effects
How often reactions happen
We found no study that gives a rate for TB-500 (21 Nov 2026), and adverse-event reports cannot give one.
Long-term effects
We found no long-term human study (21 Nov 2026), and FDA staff found no toxicity studies of TB-500 in animals or the laboratory, repeated exposure included.
Immune reactions
FDA staff wrote that, by the routes proposed to them, TB-500 “may pose a significant risk for immunogenicity”, and found no clinical study that measured it.
What a given vial contains
A lab report shows only what the tested sample from that lot held, and only for the peptide it identifies and measures.
Suspected reaction to any product? Seek medical care first, then report it. For anything about your health, a doctor who knows you is the right call.
This is a plain-English summary of public documents, studies and database records, checked on 21 Nov 2026. It is not medical advice.